Table 2.
Site of Action | Effect | Norm-Preg | HTN-Preg | Reference | |
---|---|---|---|---|---|
Bioactive Factor | |||||
VEGF | Endothelium | Vasorelaxation | 830±33 pg/mL | 594±34 pg/mL | [42] |
sFlt-1 | Endothelium | Anti VEGF | 82±26 pg/mL | 660±270 pg/mL | [43] |
Endoglin | Endothelium | Anti TGF-β | 8 ng/mL | 17 ng/mL | [44] |
Cytokines TNF-α IL-6 |
Endothelium Endothelium |
EC Dysfunction EC Dysfunction |
8±1 pg/mL 36.6±7 pg/mL |
48±13 pg/mL 104.5±28.6 pg/mL |
[45] [46] |
HIF | DNA | Gene Transcription | ↑ | ↑↑ | [27] |
ROS | Endothelium | EC Dysfunction | -- | ↑ | [27] |
Vascular Mediator | |||||
NO (Urinary Nitrite/Nitrate) | VSM | Vasorelaxation | 46.4±5.3 μmol/24 hr | 49.8±6.4 μmol/24 hr | [47] |
PGI2 | VSM | Vasorelaxation | ↑ | ↓ | [48] |
ET-1 | VSM, Endothelium | Vasoconstriction, Vasorelaxation | 1.7 pmol/L | 2.2 pmol/L | [49] |
AngII | VSM | Vasoconstriction | ↑ | ↑ | [50] |
VSM [Ca2+]i - Basal - PHE (10−5M) - AngII (10−7M) |
Myofilaments Myofilaments Myofilaments |
Basal Tone Contraction Contraction |
63 ± 5 nM 149 ±8 nM 149 ±8 nM |
109 ± 8 nM 234 ±1 nM 225 +/− 9 nM |
[51] [51] [52] |
↑↑, Greatly increased;
↑, Increased;
↓, Decreased;
--, No change, relative to nonpregnant.